Next Article in Journal
Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?
Next Article in Special Issue
Young Adults’ Intentions and Rationales for COVID-19 Vaccination Participation: Evidence from a Student Survey in Ho Chi Minh City, Vietnam
Previous Article in Journal
Experiences with Testing, Self-Isolation and Vaccination in North East England during the COVID Pandemic
Previous Article in Special Issue
Healthcare Workers’ Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study
Communication

Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives

1
Section of Pathology, Departmente of Emergency and Organ Transplantation (DETO), University of Bari “Aldo Moro”, 70124 Bari, Italy
2
Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, 70124 Bari, Italy
3
Department of Biomedical Sciences and Human Oncology, Gynecologic and Obstetrics Clinic, 70124 Bari, Italy
4
Section of Legal Medicine, Department of Interdisciplinary Medicine, Policlinico di Bari Hospital, University of Bari, 70124 Bari, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Martin H. Bluth
Vaccines 2021, 9(7), 760; https://doi.org/10.3390/vaccines9070760
Received: 12 June 2021 / Revised: 3 July 2021 / Accepted: 6 July 2021 / Published: 8 July 2021
(This article belongs to the Special Issue Vaccination Strategies for COVID-19)
The COVID-19 pandemic has affected the entire planet, and within about a year and a half, has led to 174,502,686 confirmed cases of COVID-19 worldwide, with 3,770,361 deaths. Although it is now clear that SARS-CoV-2 can affect various different organs, including the lungs, brain, skin, vessels, placenta and others, less is yet known about adverse reactions from vaccines, although more and more reports are starting to emerge. Among the adverse events, we focused particularly on skin rashes. In this short report, we describe the case of a patient vaccinated with Comirnaty, who developed a purpuric rash resistant to oral steroid therapy after 2 weeks. To date, this is one of the very few cases in which skin biopsy was performed to better characterize the histopathological picture of this rash. Finally, we conduct a literature review of the cases of rashes from SARS-CoV-2 vaccines described in the literature, with the aim of laying foundations for future, larger case studies. View Full-Text
Keywords: SARS-CoV-2; COVID-19; skin; rash; purpuric; vaccines SARS-CoV-2; COVID-19; skin; rash; purpuric; vaccines
Show Figures

Figure 1

MDPI and ACS Style

Cazzato, G.; Romita, P.; Foti, C.; Cimmino, A.; Colagrande, A.; Arezzo, F.; Sablone, S.; Barile, A.; Lettini, T.; Resta, L.; Ingravallo, G. Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives. Vaccines 2021, 9, 760. https://doi.org/10.3390/vaccines9070760

AMA Style

Cazzato G, Romita P, Foti C, Cimmino A, Colagrande A, Arezzo F, Sablone S, Barile A, Lettini T, Resta L, Ingravallo G. Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives. Vaccines. 2021; 9(7):760. https://doi.org/10.3390/vaccines9070760

Chicago/Turabian Style

Cazzato, Gerardo, Paolo Romita, Caterina Foti, Antonietta Cimmino, Anna Colagrande, Francesca Arezzo, Sara Sablone, Angela Barile, Teresa Lettini, Leonardo Resta, and Giuseppe Ingravallo. 2021. "Purpuric Skin Rash in a Patient Undergoing Pfizer-BioNTech COVID-19 Vaccination: Histological Evaluation and Perspectives" Vaccines 9, no. 7: 760. https://doi.org/10.3390/vaccines9070760

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop